A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

BACKGROUND: To determine the effect of riociguat, an oral, selective soluble guanylate cyclase stimulator, on the net digital ulcer (DU) burden in systemic sclerosis (SSc). METHODS: Participants with SSc-related active or painful indeterminate DUs were recruited in a multicenter, double-blind, rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagaraja, Vivek, Spino, Cathie, Bush, Erica, Tsou, Pei-Suen, Domsic, Robyn T., Lafyatis, Robert, Frech, Tracy, Gordon, Jessica K., Steen, Virginia D., Khanna, Dinesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724329/
https://www.ncbi.nlm.nih.gov/pubmed/31481106
http://dx.doi.org/10.1186/s13075-019-1979-7

Ejemplares similares

Ejemplares similares